Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Phase 4

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

NCT05575830 · tracked via the Priya Life Science France tracker
Sponsor
Calmy Alexandra
Phase
Phase 4
Started
2022-12-14
Last updated
2025-09-05

Condition(s) studied

RZV Vaccine (Shingrix ®)

Investigational drug(s) / intervention(s)

Recombinant Zoster Vaccine →

Recombinant Zoster Vaccine: Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

Study summary

The purpose of this study is to evaluate the efficacy and safety of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in older people (\> 50 years) living with HIV (PLWH) compared to age-matched healthy adults over a 1-year period.

Eligibility

Sex
ALL
Min age
50 Years
Max age
95 Years
Healthy volunteers
Accepted
Inclusion Criteria: For PLWH: * Be registered in the SHCS or in the ANRS CO3 Aquitaine Cohort * Age \>50 YOA * Time since cART initiation \> 10 years * Not already vaccinated with RZV * HIV viral load \<50 copies/ml (within 6 months from the last blood sampling) * Informed consent as documented by signature * (France) : Person affiliated with or beneficiary of the French social security scheme For aged/gender-matched controls * Age \>50 YOA * Not already vaccinated with RZV * Informed consent as documented by signature * (France) Not HIV infected * (France) Person affiliated with or beneficiary of the French social security scheme Exclusion Criteria: * Ongoing signs of febrile or non-febrile infection at the time of the first vaccination * Immunosuppression from the following: * Current malignant neoplasm; * primary immunodeficiency; * recent (\<2 years) solid or bone-marrow transplant or any transplant still requiring immunosuppressive therapy * Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \[an equivalent dose of prednisolone \>20 mg/day \> 3 months\], monoclonal antibodies, cytostatics, biological products, etc.) within 6 months before screening. * Administration of immunoglobulins or any blood products within 3 months preceding the first dose of vaccine or planned administration during the study period * Having received a vaccine in the last month or is expected to receive a vaccine in the next month * Having received a shingles vaccine within one year * Presented with herpes zoster in the previous year * Contra-indication to RZV * Hospitalized patients * Unable to provide informed consent or inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * Participation in another study with investigational drug within the 30 days preceding and during the present study. * (France) Pregnant or breastfeeding woman * (France) Patient governed by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)

Primary outcome measure(s)

  • Geometric mean titer (GMT) of gE-specific total IgG — Day 90
    gE-specific total IgG titers is determined by gE-specific ELISA from sera samples

Trial sites (10)

FacilityCityRegionStatus
Hôpital Saint-André, CHU de Bordeaux Bordeaux Bordeaux
SMIT - Service de Maladies Infectieuses et Tropicales Le Tripode -Groupe Hospitalier Pellegrin Bordeaux France
CHU de Bordeaux - Hôpital Haut-Lévèque Pessac Gironde
University Hospital Basel Basel Basel
Bern University Hospital (Inselspital) Bern Canton of Bern
University Hospitals of Geneva Geneva Canton of Geneva
Kantonsspital Sankt Gallen Canton of St. Gallen
Centre Hospitalier Universitaire Vaudoise (CHUV) Lausanne Canton of Vaud
University Hospital Zurich Zurich Canton of Zurich
Ente Ospedaliero Cantonale Lugano Canton Ticino
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05575830 on ClinicalTrials.gov ↗ ← All trials in France